Lung Transplantation for Pleuroparenchymal Fibroelastosis

Hospices Civils de Lyon30 enrolled

Overview

This retrospective observational study will evaluate the outcomes of lung transplantation for a rare cause of interstitial lung disease called pleuroparenchymal fibroelastosis. Data will be collected from all transplantation center in France.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Fibroelastosis

Interventions

Lung transplantation (single, lobar or bilateral lung transplantation)PROCEDURE

Lung transplantation were performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Lung transplantation (any type) for pleuroparenchymal fibroelastosis * Histologically confirmed pleuroparenchymal fibroelastosis on the recipient lungs Exclusion Criteria: * All other interstitial lung disease than pleuroparenchymal fibroelastosis * Pleuroparenchymal fibroelastosis who didn't underwent lung transplantation

Locations (4)

Marie Lannelongue Hospital

Le Plessis-Robinson, France

RECRUITING

Hopital Louis Pradel

Lyon, France

COMPLETED

Bichat Claude Bernard Hospital, APHP

Paris, France

RECRUITING

Outcomes

Primary Outcomes

Post-operative mortality

Any death after lung transplantation during the first 30 days or during the hospitalization following the lung transplantation (in-hospital mortality)

Time frame: Any death up to 90 days after lung transplantation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.